Drug Trial Radar · NCT07883590
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 13 weeks and will include 6 clinic visits.
Conditions
- Amyotrophic Lateral Sclerosis
- Cytochrome P-450 Enzyme System
Interventions
LY3873862Drug
Administered orally
CYP450 Drug CocktailDrug
CYP450 Drug Cocktail (caffeine, midazolam, flurbiprofen, dextromethorphan and omeprazole) administered orally.
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients with One or More Treatment Emergent Adverse Events Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline, Day 28
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Sutter Health Research Institute- California Pacific Medical Center, Van Ness Campus
San Francisco, California
University of Colorado Anschutz
Aurora, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Northwestern University
Chicago, Illinois
Healey and AMG Center for ALS at Mass General Hospital
Boston, Massachusetts
Montreal Neurological Institute and Hospital
Montreal, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.